Overall, these data provide further support for the use of JAK inhibitors in T1D, accompanied by reduced functions of Lnk with the risk variants of LNK/SH2B3 gene (Wang et al, 2016) for T1D. This evidence concerns the gene SH2B3 and type 1 diabetes mellitus.